ATYR News & Events

aTyr Pharma announced that the U.S. Food and Drug Administration, FDA, has accepted the Company's meeting request to discuss its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis. The Type C meeting is scheduled for mid-April 2026. "We look forward to meeting with the FDA in mid-April to review the results of our Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease," said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. "We expect to provide an update regarding the outcome of the meeting following the receipt of the official meeting minutes."

"In September, we announced results from our Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease. While we did not meet the primary endpoint, efzofitimod is the first investigational therapy to exhibit improvements in quality of life across multiple disease-related health outcomes while also reducing steroid burden in patients with pulmonary sarcoidosis," said Sanjay S. Shukla, President and Chief Executive Officer of aTyr. "Treatment options for pulmonary sarcoidosis are limited and can include a significant reliance on the use of oral corticosteroids, which often have significant side effects. There remains an urgent need for a new safe and effective treatment for patients with chronic, symptomatic disease."